当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Pranab Maiti* and Rajiv Sharma
Inflammatory Bowel Disease (IBD), consisting of Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a chronic intestinal disorder arises due to the damaged intestinal epithelium tissue which most often leads to relapsing. Major treatment options range from dietary intervention at an early stage of the disease, to the use of steroids or anti-inflammatory drugs for the severe most conditions. However, the side effects and associated comorbidities which bring disease recurrences points towards the unmet needs of the existing treatment options which are limited to their non-holistic mechanistic functionality. Among them, many drugs work specifically by acting locally on the gut tissue, in other words at the site of the disease; both to exert maximal efficacy as well as to avoid undesired side effects. Here we have reviewed the recent interests in the gut restricted therapeutic approaches for new IBD therapies.